Navigation Links
Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
Date:3/13/2008

Lilly to Acquire Exclusive Rights to Gastrin Based Therapies Program for

Diabetes

INDIANAPOLIS and TORONTO, March 13 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and Transition Therapeutics Inc. (TSX: TTH; Nasdaq: TTHI) today announced that the two companies have entered into a licensing and collaboration agreement granting Lilly exclusive worldwide rights to develop and commercialize Transition's gastrin based therapies, including the lead compound TT-223, which is currently in early Phase II testing. Gastrin based therapies are an emerging class of potential disease-modifying therapies for patients with diabetes, and have been shown to provide sustained improvement in glycemic control in preclinical models and early clinical studies. Sustained improvement in glycemic control is a key goal for patients with diabetes in order to alleviate the symptoms of hyperglycemia and to prevent diabetic complications, thereby improving their overall quality of life.

Under the terms of the agreement, Transition will receive a $7 million upfront payment, and may also receive up to $130 million in potential development and sales milestones, as well as royalties on sales of gastrin based therapies if any product is successfully commercialized. Transition and Lilly will both participate in the currently planned phase II clinical trial with lead compound TT-223 in type 2 diabetes. Thereafter, Lilly will be responsible for further development activities and the commercialization of all gastrin based therapeutic products worldwide. Other terms of the deal were not disclosed.

"This agreement represents an exciting new direction for Lilly's diabetes care research," said David Moller, M.D., Li
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. ImaRx Therapeutics Transitions Business Strategy
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...S, France, July 24 /- NicOx...p-line results from the 52-week,open label safety ...ion of,the 301 phase 3 study for naproxcinod. The ... efficacy was maintained for the one-year duration... assessment scale. In,addition, the results showed...
(Date:7/23/2008)...3 /- Sound Pharmaceuticals (SPI) has ... the FDA for the clinical,testing of a proprietary...otherapy induced hearing loss or ototoxicity. The ... tested in advanced stage lung cancer,and head and...motherapy.,This marks the second development progr...
(Date:7/23/2008)...s Some Areas of the Body Have Greater Concentratio...3 /PRNewswire-USNewswire/ -- Fat removed,from the ...was found to be,an excellent source of stem cells,...reas of the body, reports a Brazilian-based study ... the official medical journal of the,American Soci...
(Date:7/23/2008)... on IND-Enabling Work with Protein Therapeutics th...ement System, CAMBRIDGE, Mass., July 23 /PRNewswi...t has initiated a corporate growth plan with the,a...utive officer and the,establishment of its headqua...odruff Emlen, M.D., a co-founder of the company wh...
Breaking Medicine Technology:NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Endocare Stock to Commence Trading on NASDAQ 3184 1Endocare Stock to Commence Trading on NASDAQ 3184 2Ingenuity Systems Launches New Metabolomics Solution Within IPA 1137 1Ingenuity Systems Launches New Metabolomics Solution Within IPA 1137 2Marriage 26 Family 3A Celebrating Holiday Traditions 3178 1Marriage 26 Family 3A Celebrating Holiday Traditions 3178 2QLT acquires leading edge ocular drug delivery system from ForSight Labs 3176 1QLT acquires leading edge ocular drug delivery system from ForSight Labs 3176 2QLT acquires leading edge ocular drug delivery system from ForSight Labs 3176 3QLT acquires leading edge ocular drug delivery system from ForSight Labs 3176 4QLT acquires leading edge ocular drug delivery system from ForSight Labs 3176 5
(Date:7/25/2008)...ncial results -, LAVAL, QC, July 25 /PRNewswire-F...) today announced that it will host a conference c...ss its second quarter 2008,financial results. Labo...l,results via news release at approximately 7:00 a...by telephone, dial 416-646-3095 or,1-800-814-4859....
(Date:7/25/2008)...stCall/ -- Thoratec,Corporation (Nasdaq: THOR ) a...ry support therapies to save, support and restore ...t its operating results for the second,quarter and... 31., The company will hold a conference call to ...ties to all interested parties at 1:30 p.m.,Pacif...
(Date:7/25/2008)...unction, increases asthma risk, studies find, ,... clean, fresh-smelling home may actually be bad fo...and air freshening products you use. , Recent r...s or air fresheners that contain a certain volatil...ne (1,4 DCB), can reduce lung function by 4 percen...
(Date:7/25/2008)... Society for Gastrointestinal Endoscopy (ASGE) has... bariatric surgery patient. The rising prevalence ... surgical interventions led to a marked increase i... the U.S., from 13,365 in 1998 to 102,794 in 2003....ive patient and the postoperative patient, and app...
Breaking Medicine News(10 mins):Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Thoratec Schedules Second Quarter 2008 Conference Call, Webcast 2Health News:Health Hazards in Household Cleaners Exposed 2Health News:Health Hazards in Household Cleaners Exposed 3Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 3
...o epidemiologists has provided new information on ... bacteria in Post menopausal women and the associ...s showed that women infected with four bacteria kn...ore likely to have more severe oral bone loss than...
... ruled that Ontario residents can get cold and all...l grocery and corner stores . The Ontario Superio...harmaceutical regulators and the Ontario College o...elling medications containing ephedrine and pseudo...
...x Planck Institute for Brain Research in Frankfurt...icago have discovered that nocturnal fruit bats (...he retinas of most mammals contain two types of ph...ht vision and colour vision, and the more sensitiv...
...rogramme has been heavily promoted by the UK gover...alth care and deliver long term cost savings . But...e and question whether expert patients consume few...hief medical officer, Sir Liam Donaldson, conclude...
Other Medicine News:Health News:Post Menopausal Women are Prone to Gum Disease 2Health News:Canadian Court Rules Grocery Shops can Sell Cold Medications Containing Pseudoephedrine 2Health News:Research on Fruit Bats 2Health News:Research on Fruit Bats 3
... IOL power calculation software. All A-scans and A...e module with SRK II, SRKT, Holladay Dioptimum and...H 5100e are equipped with corneal compression dete...eadings. The only A-Scan in the world with corneal...
The AccuSonic A-scan makes it easy to obtain extreme accuracy and improved patient outcomes. Obtain accurate measurements with industry leading signal acquisition and processing.
The UD-1000 incorporates the latest ultrasound technology for eyecare specialists. It is the ideal choice for your modern diagnostic laboratory. The UD-1000 combines a powerful B-sector scan system w
The UD-6000 combines all the functions of modern ultrasound diagnostics used in ophthalmology: The latest generation high resolution A/B-sector scanner, a diagnostic A-mode scanner with an optional p
Medicine Products: